Get started
Author

Manjola Balliu

Observed names: Balliu, Manjola, M Balliu, M. Balliu
ORCID: 0000-0003-3387-812X
Observed ORCID: 0000-0003-3387-812X
OpenAlex ID: A5038401147
Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
2014 · on behalf of the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators, A M Vannucchi, et al. · Leukemia · 86
PDF
Calreticulin Ins5 and Del52 mutations impair unfolded protein and oxidative stress responses in K562 cells expressing CALR mutants
2019 · Simona Salati, Elena Genovese, et al. · Scientific Reports · 58
PDF
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
2024 · Paola Guglielmelli, Barbara Mora, et al. · American Journal of Hematology · 39
PDF
Inhibitors of the PI3K/mTOR pathway prevent STAT5 phosphorylation inJAK2V617Fmutated cells through PP2A/CIP2A axis
2017 · Niccolò Bartalucci, Laura Calabresi, et al. · Oncotarget · 39
PDF
RETRACTED: HDAC ‐inhibitor (S)‐8 disrupts HDAC 6‐ PP 1 complex prompting A375 melanoma cell growth arrest and apoptosis
2014 · Manjola Balliu, Luca Guandalini, et al. · Journal of Cellular and Molecular Medicine · 29
PDF
Effectiveness of the Histone Deacetylase Inhibitor (S)-2 against LNCaP and PC3 Human Prostate Cancer Cells
2013 · Anna Laurenzana, Manjola Balliu, et al. · PLoS ONE · 29
PDF
Inhibition of ERK1/2 signaling prevents bone marrow fibrosis by reducing osteopontin plasma levels in a myelofibrosis mouse model
2023 · Elisa Bianchi, Sebastiano Rontauroli, et al. · Leukemia · 23
PDF
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
2023 · Paola Guglielmelli, Chiara Maccari, et al. · Blood Cancer Journal · 20
PDF
Activated IL-6 signaling contributes to the pathogenesis of, and is a novel therapeutic target for, CALR-mutated MPNs
2021 · Manjola Balliu, Laura Calabresi, et al. · Blood Advances · 18
Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: The crucial role of PTEN
2009 · Cristina Cellai, Anna Laurenzana, et al. · Experimental Hematology · 18
PDF
The Response to Oxidative Damage Correlates with Driver Mutations and Clinical Outcome in Patients with Myelofibrosis
2022 · Elena Genovese, Margherita Mirabile, et al. · Antioxidants · 17
PDF
Design, synthesis and preliminary evaluation of a series of histone deacetylase inhibitors carrying a benzodiazepine ring
2013 · L. Guandalini, M. Balliu, et al. · European Journal of Medicinal Chemistry · 16
CALR mutation burden in essential thrombocythemia and disease outcome
2024 · Paola Guglielmelli, Natasha Szuber, et al. · Blood · 15
PDF
HDAC1 controls CIP2A transcription in human colorectal cancer cells
2016 · Manjola Balliu, Cristina Cellai, et al. · Oncotarget · 15
PDF
Inhibition of CXCR1/2 reduces the emperipolesis between neutrophils and megakaryocytes in the Gata1low model of myelofibrosis
2023 · Francesca Arciprete, Paola Verachi, et al. · Experimental Hematology · 14
The new low‐toxic histone deacetylase inhibitor S‐(2) induces apoptosis in various acute myeloid leukaemia cells
2011 · C. Cellai, M. Balliu, et al. · Journal of Cellular and Molecular Medicine · 14
PDF
Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
2021 · Simone Romagnoli, Niccolò Bartalucci, et al. · Biomarker Research · 5
PDF
Combinatorial BCL2/BCL2L1 expression predicts clinical response to ruxolitinib in myelofibrosis
2025 · Giacomo Coltro, Viola Videschi, et al. · Biomarker Research · 3
PDF
Calr Variant Allele Frequency in Essential Thrombocythemia: Molecular Associations and Impact on Disease Phenotype and Outcome
2023 · Paola Guglielmelli, Natasha Szuber, et al. · Blood · 2
The Immature Morphology of the Megakaryocytes Present in the Bone Marrow of Patients with Myelofibrosis Reflects Changes in the Frequency of Functionally Distinctive Subpopulations
2022 · Francesca Arciprete, Maria Zingariello, et al. · Blood · 2
Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells
2022 · Laura Calabresi, Manjola Balliu, et al. · Methods in cell biology · 2
A Novel, Ruxolitinib‐Sensitive, CCDC6 :: JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera‐Like, Myeloproliferative Neoplasm
2025 · Niccolò Bartalucci, Danilo Tarantino, et al. · American Journal of Hematology · 1
PDF
POSTER: MPN-545: The Selective PI3KδInhibitor Roginolisib Synergizes With JAK Inhibitors in Progenitor Cells From Naïve and JAK Inhibitor–Refractory/Resistant Patients With Myelofibrosis
2026 · Manjola Balliu, Valentina Boldrini, et al. · Clinical Lymphoma Myeloma & Leukemia
MPN-545: The Selective PI3KδInhibitor Roginolisib Synergizes With JAK Inhibitors in Progenitor Cells From Naïve and JAK Inhibitor–Refractory/Resistant Patients With Myelofibrosis
2026 · Manjola Balliu, Valentina Boldrini, et al. · Clinical Lymphoma Myeloma & Leukemia
Homozygosity of germ line JAK2 46/1 haplotype contributes to phenotype and outcome diversity in polycythemia vera
2026 · Paola Guglielmelli, Chiara Maccari, et al. · Blood Neoplasia
Works count: 41
Citation count: 465
H-index: 14
I10-index: 16
Year
Topic
Type